Novartis licensed exclusive worldwide rights (ex-Japan) to Kyorin's KRP-M223, a preclinical MRGPRX2 antagonist for chronic spontaneous urticaria, for $55M upfront and up to $777.5M in milestones plus tiered royalties. Total potential value ~$830M.
Key facts
AnnouncedMar 03, 2025
Deal value$833M
Deal typeLicensing/Option
Therapeutic areaChronic spontaneous urticaria and mast cell-mediated diseases
IndicationsChronic spontaneous urticaria and mast cell-mediated diseases
Key assetsKRP-M223
MechanismMRGPRX2 antagonist (preclinical small molecule)